AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00981201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Months 4-6:~By mouth twice daily.
Trial: NCT01199965
Drug: MAP0004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
Trial: NCT01199965
Drug: IV DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV DHE administered at Visit 2 or 3 as per protocol
Trial: NCT00319956
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
Trial: NCT02051686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive a similar volume load of normal saline and maintenance doses.
Trial: NCT02405780
Drug: FKB327
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
Trial: NCT02405780
Drug: Humira®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
Trial: NCT02272868
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
Trial: NCT02122081
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04550949
Drug: QL1206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
Trial: NCT02678195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Trial: NCT01251926
Drug: EZN-2208
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00265304
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01576588
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
Trial: NCT02762097
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline would be injected into uterine cavity to delineate defects
Trial: NCT02579096
Drug: Placebo, vehicle control (febuxostat-shaped)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets resembling febuxostat will be given with allopurinol.
Trial: NCT02579096
Drug: Placebo, vehicle control (allopurinol-shaped)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules resembling allopurinol will be given with febuxostat.
Trial: NCT00547547
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
Trial: NCT02494713
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
Trial: NCT03657342
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
Trial: NCT03777033
Drug: Prophylactic protocol with Ca and Vit D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet
Trial: NCT00159965
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flexible dose placebo
Trial: NCT00311961
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00311961
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02202525
Drug: Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02793544
Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Trial: NCT03565029
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capecitabine and Oxaliplatin (4x cycles)
Trial: NCT02793544
Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Trial: NCT02793544
Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Trial: NCT02793544
Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight.
Trial: NCT00449878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02046928
Drug: A6
RxNorm normalized name: CYP2A6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
Trial: NCT02495324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of placebo PO daily
Trial: NCT04282980
Drug: DCC-2618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral kinase inhibitor
Trial: NCT03763110
Drug: antibiotic paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996
Trial: NCT03558477
Drug: YYD601 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYD601 1
Trial: NCT02004704
Drug: GZ402665
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion
Trial: NCT01848730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02564796
Drug: Epoetin Alfa and Iron
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
Trial: NCT02564796
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
Trial: NCT03583697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
Trial: NCT03996486
Drug: BAY1093884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
Trial: NCT00114530
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
Trial: NCT03572972
Drug: Antiplatelets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for NVAF patients
Trial: NCT01817530
Drug: 0.5 mg estradiol / 0.1 mg norethindrone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral hard capsule
Trial: NCT01817530
Drug: 1 mg estradiol / 0.5 mg norethindrone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral hard capsule
Trial: NCT01817530
Drug: E2/NETA placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral hard capsule
Trial: NCT00001880
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
Trial: NCT01073995
Drug: Kenalog and Sensorcaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Trial: NCT01968798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg enteric-coated placebo, taken daily
Trial: NCT02598102
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac for pain relief
Trial: NCT02467400
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00287482
Drug: Essiac
RxNorm normalized name: ESSIAC TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02975336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to M2951 orally for 52 weeks.
Trial: NCT03305055
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Information included in arm descriptions
Trial: NCT00622908
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of ISV-403 TID, 5 days
Trial: NCT00866684
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: control arm Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
Trial: NCT03268382
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00750997
Drug: hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
Trial: NCT03274596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03268382
Drug: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT03302650
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive normal saline.
Trial: NCT03302650
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive norepinephrine infusion adjusted according to blood pressure
Trial: NCT01694264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
Trial: NCT03658135
Drug: BIIB092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB092 is an investigational monoclonal antibody directed at tau protein
Trial: NCT01545635
Drug: Fresh Frozen Plasma blood type 0, A, B and AB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
Trial: NCT03198013
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04195906
Drug: Experimental: SNF472
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
Trial: NCT03198013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04195906
Drug: Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
Trial: NCT02637193
Drug: Drug - placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 16 days
Trial: NCT02008318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02095418
Drug: Mycophenolate mofetil, Corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
Trial: NCT02095418
Drug: Corticosteroids, Mycophenolate mofetil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
Trial: NCT02236130
Drug: Oral pain medication Acetaminophen with Hydrocodone
RxNorm normalized name: acetaminophen / hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with Hydrocodone
Trial: NCT01105650
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously, 60 mg/kg, days -5 and -4.
Trial: NCT03317197
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
Trial: NCT03317197
Drug: Experimental Group 1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
Trial: NCT02281773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03317197
Drug: Experimental Group 3
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
Trial: NCT01697020
Drug: Mercaptopurine 20mg/ml oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg
Trial: NCT01697020
Drug: Mercaptopurine 50mg tablet
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg
Trial: NCT02238223
Drug: Alesion®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03336541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
Trial: NCT00440583
Drug: chemotherapy followed by Zevalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
Trial: NCT01364649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine Placebo-matching capsules
Trial: NCT02114671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, oral
Trial: NCT00280436
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04418141
Drug: CN1
RxNorm normalized name: TRACH TUBE,SZ 10 CUFFED SHLY #10CN10R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
Trial: NCT00915057
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
Trial: NCT04621630
Drug: PN-235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT04621630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT02277769
Drug: Placebo (for Dupilumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
Trial: NCT04198298
Drug: EndoSequence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
Trial: NCT04198298
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
Trial: NCT01536223
Drug: TPF (docetaxel plus cisplatin and 5-fluorouracil) group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
Trial: NCT02799602
Drug: Standard ADT (androgen deprivation therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by the treating physician.
Trial: NCT02799602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
Trial: NCT03792191
Drug: Intrathecal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Trial: NCT02133339
Drug: TRN-157
FDA approved: no
EMA approved: no
PMDA approved: no